In a study, patients who underwent salvage cryotherapy for radiorecurrent prostate cancer had cancer-specific and metastasis-free survival rates of 81% and 78%, respectively, at 12 years.
Cryoablation also cuts the need for opioids at 24 hours post-treatment and at 3 months.
Oncologic outcomes are similar for focal and total cryoablation for localized prostate cancer, but patients report significantly better sexual function after focal cryoablation.
The recurrence group had significantly larger tumors than the no-recurrence group.
A PSA nadir below 0.4 ng/mL offers the best long-term biochemical progression-free survival, study shows.
Men who underwent whole-gland cryoablation had an estimated 5-year biochemical progression-free survival rate of 59.1%.
Study reveals comparable rates of freedom from biochemical failure at 5 years.
Lapascopic and percutaneous cryoablation for small renal masses are associated with similar survival, researchers say.
Focal and whole-gland approaches may provide alternatives for recurrent PCa after radiotherapy
Patients who underwent the procedure experienced no significant change in renal function.
